Abstracts tagged "collagen and interleukins (IL)"

Abstract Number: 475 • 2016 ACR/ARHP Annual Meeting
N-3 Polyunsaturated Fatty Acids in Fat-1 Mice Attenuate Collagen Antibody-Induced Arthritis
Seung Cheol Shim¹, In-Seol Yoo¹, Chan Keol Park¹, Ji-Young Kim¹, Young Mo Kim², Kyu Lim³, Kyung Hee Kim⁴, Jinhyun Kim¹ and So Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, The Republic of, ²Department of Orthopedic Surgery, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, The Republic of, ³Department of Biochemistry, Cancer Research Institute, College of Medicine, Chungnam National University, Daejeon, Korea, The Republic of, ⁴Department of Pathology, Cancer Research Institute, College of Medicine, Chungnam National University, Daejeon, Korea, The Republic of
Background/Purpose: N-3 polyunsaturated fatty acids (PUFA) have anti-inflammatory effects and were considered useful for the treatment of rheumatoid arthritis (RA), however the mechanism is still…
Abstract Number: 1048 • 2014 ACR/ARHP Annual Meeting
Oncostatin M Suppresses Activation of IL-17/Th17 Via Suppressor of Cytokine signaling3 (SOCS3) Regulation in CD4+ T Cells
Young Ok Jung^1,2, seon Yeong Lee³, Sung Yeon Lee⁴, Mi-La Cho³ and Hea-Jin Son⁵, ¹Rheumatology dept, Internal medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, ²Rheumatology dept, Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, ³Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, ⁴Department of Internal Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea, ⁵Rheumatism Research Center, Catholic Institutes of Medical Science, The Catholic University of Korea, Seoul, South Korea
Background/Purpose Oncostatin M (OSM) is a pleiotropic cytokine that belongs to the interleukin(IL)-6 group of cytokines. High level of OSM were detected in synoviums of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].